FDX1 and nonpapillary renal cell carcinoma: To test whether FDX1 manipulation could alter the biological activities of ccRCC cells, we utilized three siRNAs to knock down FDX1 in OSRC-2 cells, which efficiently silenced FDX1 at both the mRNA (Figure 4C) and protein levels (Figure 4D).